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Summary 
The preferential usage of certain T cell receptor (TCK) V3 genes has been well established in 
several major histocompatibility  complex (MHC)-restricted immune responses. However, V3 
usage among allogeneic responses remains unclear. Because recent findings of ours and others 
indicate that V38 predominates in certain La-restficted, peptide-spedfic responses, we examined 
the V38 usage in allogendc responses to L  a. To selectively recognize the L  a molecule, cells from 
BALB/c-H-2  am (din2), the La-loss mutant mouse, were stimulated in vitro or in vivo with wild- 
type BALB/c cells. We report here that after the intraperitoneal  administration of the anti-V38 
monoclonal antibody (mAb) F23.1, peripheral V/~8 T cells were depleted from din2 mice. This 
in vivo depletion abrogated the ability of dm2 splenocytes to mount a primary response to L  a 
molecules. This abrogation was specific, since the response of V/~8-depleted dm2 cells to Kb/D  b 
antigens was the same as that of control nondepleted dm2 cells. Furthermore, in vivo depletion 
of V38  cells was found to cause a dramatic  prolongation of La-disparate skin grafts  (mean 
survival time [MST] 22.1  _+  2.1 vs.  10.3  _+  1.1 d for saline-treated controls,  or 10.9  _+  1.7 
d for controls treated with mAb KJ23 to V/317). By contrast,  V/38 depletion had no effect on 
recipients  grafted with haplotype-mismatched  skin or single Dk-locus-disparate skin.  These 
findings demonstrate that V38 + T cells predominate in allogendc response to L  a but not other 
alloantigens.  The effect of V38 depletion  was found to be even more dramatic  on recipients 
grafted with  La-disparate vascularized heart transplants  (MST  >  100  vs.  8.6  _+  0.5  d  for 
controls).  In total,  these findings establish the efficacy of using mAb to the V3 gene family 
to specifically and significantly enhance the survival of allografts. The implications of detecting 
V38 usage in both alloreactive or MHC-restricted TCR responses to the same class I molecule 
are discussed. 
T 
he function of the immune system is to discriminate self 
from non-self. For example, the cellular arm of the im- 
mune system identifies virus-infected cells, malignant cells, 
or genetically disparate tissue transplants using CD8 + CTL. 
These CTL bear receptors (TCK) capable of specific iden- 
tification of appropriate target cells that express foreign pep- 
tides bound to self-class I MHC molecules (1). Such immuno- 
genic peptides are 8-9 amino acids long and are bound to 
the antigen binding groove formed by the or1 and oe2 do- 
mains of the class I molecule (2). The TCK is a disulfide- 
linked orb heterodimeric glycoprotein with a number of in- 
variant associated  molecules (3, 4). The heterogeneity of TCK 
molecules  that is required to recognize the abundance of  poten- 
tial foreign antigens  is achieved by somatic recombination 
of V-(D)-J segments to form a single functional transcrip- 
tional  unit encoding each ot or 3  TCR chain.  Since there 
are several different alternative V-(D)-J segments, as well as 
additional junctional diversities, innumerable distinct  TCR 
are generated, each with unique structures (5-7). Even though 
it is dear that structural differences in both TCR o~ and 3 
chains determine their specific interaction with MHC-pep- 
tide complexes, the details have yet to be fully elucidated. 
Recent data support a model whereby distinct regions of each 
o~ and/3 chain interact with the MHC molecule or its bound 
peptide ligand (7). 
Given the large number of different combinational  TCR 
possibilities, as well as the various manners by which TCR 
and MHC-peptide complexes potentially interact, it might 
be expected that most immune responses would show di- 
verse TCR usage. However, some interesting examples of 
limited TCR usage have recently been noted. For instance, 
the Ld-restricted immune response of a BALB/c mouse after 
CMV infection  was shown to preferentially use VB8 + T 
cells (8). Similarly,  predominant V38 usage was also observed 
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ciated  tum-  peptide  (Solheim,  J.  C.,  M.  A.  Alexander- 
Miller, J. M. Martinko, andJ. M. Connolly, manuscript sub- 
mitted for publication). In studies of Ka-restricted responses, 
CTL specific for a single Plasraodium berghei circumsporozoite- 
derived peptide displayed diverse TCR (9) in contrast to ones 
specific for an HLA-CW3 peptide that display limited TCR 
diversity (10). The structural basis for why particular immune 
responses have been found to show limited TCR usage re- 
mains  unclear. 
Our understanding  of the diversity of TCR usage in al- 
logeneic responses to class  I,  such as allograft rejection,  is 
potentially important  for both mechanistic and therapeutic 
reasons. However, allogeneic recognition of class I has an ad- 
ditional  level  of complexity compared with  the syngeneic 
systems mentioned above. This uncertainty stems from the 
fact that it remains unclear whether alloreactive T cells recog- 
nize predominantly polymorphic MHC determinants or their 
bound ligands. If bound ligands play a key role in allorecog- 
nition, then tissue-specific antigens could significantly influence 
the diversity of alloreactive CTL involved in allograft rejec- 
tion. Initial studies analyzing TCR gene usage during end- 
stage transplantation rejection episodes or in vitro allorecog- 
nition have been conflicting.  Certain studies have demonstrated 
the preferential usage of specific TCR variable regions (11, 
12), whereas others have reported high levels of diversified 
gene usage (13-15). It is dit~cult to understand the implica- 
tion of these studies on TCR diversity because of the expres- 
sion of multiple major and minor alloantigenic differences 
between host and donor tissue. To alleviate this problem, we 
have investigated the in vitro and in vivo response to a single 
class  I  alloantigen,  the L d molecule of the mouse.  Studies 
of allorecognition  using  L  a have  two  notable  advantages. 
First, La-spedfic responses can be generated using the Ld-loss 
mutant  (16) mouse strain BALB/c-H-2  ~2 (dm2) t. Second, 
we and others (8; Solheim et al.,  manuscript submitted for 
publication) have generated a background of relevant infor- 
mation  concerning  the  TCR  recognition  of Ld-peptide 
complexes in  syngeneic immune  responses. 
In this communication,  we demonstrate that the in vivo 
depletion of the V~8 + T  cell subset results in a significant 
decrease in  the  dm2  anti-L a allogeneic response.  Further- 
more, recipient din2 mice depleted of V/38 + cells show dra- 
matic and specific prolongation of skin or heart allograft sur- 
vival.  These  findings  thus  represent  a  dear  example  of 
dominant V~ usage in an in vivo primary response to a class 
I  alloantigen.  The implications  of these findings  on TCR 
recognition of allogeneic versus syngeneic class I-pcptide com- 
plexes are discussed. 
Materials and Methods 
Animals.  Female C57BL/6,  BALB/c, B10.HTT,  BALB.K, 
(B10.AKM x  dm2)F1, and BALB/c-H-2  d~ (din2) mice (see Table 
1) were bred and maintained in the animal facility of Donald C. 
t Abbreviation used in  this paper: din2, Ld-loss mutant mouse strain 
BALB/c-H-2  am2. 
Shreffler, Washington University School of  Medicine. All mice were 
used at 6-12 wk of age and were cared for according to National 
Institutes  of Health guidelines. 
Tumor Target Cell Lines.  The mastocytoma P815, lymphoma 
EL-4, thymoma  R1.1,  and Ld-transfected thymoma RI.IL  d (see 
Table 1) were maintained at 37~  95% air/5.0% CO2 in DME 
(Gibco Laboratories, Grand Island, NY) containing 10% FCS (Hy- 
clone Laboratories, Logan, UT), 2 mM r-glutamine, and 100 U/ml 
penicillin-streptomycin  (Washington  University  Tissue Culture 
Center). 
mAb Usedforln Vivo Depletions.  The anti-V~8 mAb F23.1 (17), 
and anti-VB17 mAb KJ23 (18) (generously provided by Dr.  O. 
Kanagawa, Department of Pathology, Washington University) are 
mouse IgG2a isotype that were grown in our laboratory as culture 
supernatant and ascites fluid and were protein A af~nity chroma- 
tography purified. 
In Vivo Depletion of V~8 + T Cells.  Groups of three identically 
treated experimental dm2 mice received three independent 500/~g 
i.p. injections of protein A-purified F23.1 mAb in 0.5 ml normal 
saline (days 0,  + 2, and  + 4) before harvesting of splenocytes (day 
+ 7) for analysis via flow cytometry (FACS|  Becton Dickinson 
& Co.,  Mountain  View, CA).  Control  dm2  mice received in- 
traperitoneal injection of the vehicle, 0.5 ml 0.9% normal saline 
without F23.1 before splenocyte harvest and analysis. 
Flow Cytometry.  Briefly, 2-4  x  10  s cells were plated in the 
wells of round-bottomed microtiter phtes, washed once with HBSS 
(lacking phenol  red) containing  0.2%  FCS/0.1%  sodium azide 
(FACS  |  medium),  and were incubated with a saturating  concen- 
tration ofF23.1 n'LAb, biotinylated anti-CD8 (Ly2) (Pharmingen, 
San Diego, CA), or with FACS  |  medium alone for 30 min at 4~ 
The cells were washed three times with FACS  |  medium, and then 
incubated with a saturating concentration of fluorescein-conjugated 
F (ab')2 fragment of Fc-specific goat anti-mouse IgG, (Organon- 
Teknika-Cappel, Durham,  NC) or Streptavidin-PE (Caltag Labora- 
tories, South Francisco, CA) for 30 rain at 4~  washed with FACS  | 
medium  three  times,  and finally resuspended in 0.5  ml FACS  | 
medium.  Fhorescein and PE-labded  calls were analyzed using a 
FACScan  |  (Becton Dickinson & Co.) equipped with an argon hser 
tuned to 488 nm and operating at 150 mW of power. Fluorescent 
four-quadrant,  two-color contour plots were generated with loga- 
rithmic amplification of fluorescence emitted by single viable cells. 
Each sample analyzed comprised a minimum  of 2.5  x  104 ceils 
and was statistically evaluated using the CONSORT 30 computer 
software (Becton Dickinson  & Co.). 
Generation of Specific din2 Anti-H-2L ~ CTL.  Splenocytes  used 
for the generation  of primary  din2  anti-H-2L d CTL were har- 
vested from control saline- or F23.1-treated dm2 mice 7 d after 
the initial intraperitoneal injection of the mAb F23.1. At the com- 
pletion of BALB/c skin graft rejection,  spleen cells used for the 
generation  of secondary dm2  anti-H-2L d CTL  were  harvested 
from control saline- and F23.1-treated dm2 recipient mice. 7.5  x 
106 responding spleen cells were cecultured  in 24-well tissue cul- 
ture plates (Costar  Corp.,  Cambridge,  MA) with 3.5  x  106 ir- 
radiated (2,000 tad) stimulating BALB/c spleen cells at 37~  95% 
air/5% COz for 5 d in a final vohme of 2 ml. At the completion 
of this incubation  period,  effector cells were harvested, washed, 
and resuspended in DME supplemented  with 10% FCS. 
SlCr-Release Assay.  104 target ceils were labeled with 200/~Ci 
StCr (NaSlCrO+, 1 mCi/ml; Amersham Corp., Arlington Heights, 
IL) in 100 ~1 of DICE supplemented with 10% FCS for 1 h at 
37~  in 95% air/5% CO~. Radiolabeled target ceils were washed 
three  times, counted,  and resuspended.  2  x  103 calls in  100/zl 
DME with 10% FCS were added to V-bottomed microtiter plates 
36  Anti-V/58  Prolongs  Ld-disparate  Aliograft  Survival (ICN Biomedicals,  Inc., Costa Mesa, CA). For antibody blocking, 
10/~g of F23.1 was added 15 min before the addition of the respec- 
tive targets and remained throughout the 4-h SlCr-release assay. 
Effector cells were harvested, resuspended, diluted to the appro- 
priate concentration, and dispensed into the V-bottomed plates. 
The plates were spun at 50 g for 2 rain and incubated for 4 h at 
37~  and 95%  air/5% CO2. At completion of the incubation 
period, the plates were spun at 500 g and 100 t~l of the supematant 
was harvested and counted  on a gamma counter  (model 1272 
Clinigamma; LKB Instruments,  Turku, Finhnd). The mean of 
triplicate samples was calculated and percent SlCr-release was de- 
termined according to the following equation: percent SlCr-release 
￿9  ,  100x [(experimental SlCr-release  -  control  SlCr-release)/ 
(maximum  StCr-release  -  control  SlCr-rehase)]. Where  ex- 
perimental SlCr-release represents counts from target cells mixed 
with effector cells, control  S*Cr-release represents counts  from 
target cells incubated with medium alone (spontaneous release), 
and maximum SlCr-release represents counts from target cells ex- 
posed to 5% Triton X-100. For data presented in this paper, the 
SEM percent lysis was <5% of the value of the mean. 
Skin Grafting.  Female  din2 and (B10.AKM x  dm2)F1 mice 
were engrafted on the left and right dorsal thorax with full thick- 
ness abdominal B10.HTT, C57BL/6,  BALB.K, or BALB/c skin 
grafts on day 0 according to an adaptation of the method of Bil- 
lingham and Medawar (19). On days -2, 0, and +3, experimental 
din2 mice were injected intraperitoneally with 500/~g  aifinity- 
purified  F23.1 mAb,  while  control  din2  mice received an in- 
traperitoneal injection of 0.5 ml normal saline without F23.1, or 
500/~g of the isotype-matched mAb KJ23 (anti-V317). Bandages 
were removed on day + 7, and the grafts were scored daily until 
rejection was complete (defined  as loss >90% of  the grafted tissue). 
Cardiac Transplantation.  Intraabdominal  heterotopic  cardiac 
transplantation was performed according to a modified method of 
Corry et al. (20). 
BALB/c donors received  300 U of  heparin intravenously 10 rain 
before surgery. The superior and inferior vena cavae were ligated 
and the heart perfused with 2 ml of 4~  lactated Ringer's solution 
via the inferior vena caw. The pulmonary artery was divided at 
its bifurcation and the ascending aorta transected proximal to the 
origin of the innominate artery. After mass ligation of the pulmo- 
nary veins, the heart was removed  and stored  in 4~  lactated  Ringer's 
solution. 
The donor's ascending aorta was anastomosed end to side to 
the recipient infrarenal abdominal aorta with a running 10-0 der- 
malon suture (courtesy of  Davis & Geck, Co., Danbury, CT). The 
donor pulmonary artery was anastomosed end to side to the recip- 
ient inferior vena caw with a 10-0 dermalon suture in a running 
fashion. Graft ischemia was consistently <20 min, and all grafts 
began beating promptly after revascularization.  Graft function was 
assessed by daily cardiac palpation, and graft rejection, defined as 
complete cessation of  ventricular contraction, was confirmed histo- 
logically. 
Statistical Analysis of Cardiac Allognafi and Skin Gnarl Survival 
Data.  Allograft  survival data  were  evaluated for  statistical 
significance  by the Kaphn-Meier analysis,  and considered  significant 
at p < 0.05. 
Results 
Blocking of the In Vitro Response to L ~ Using 1:23.1.  Be- 
cause of recent studies of ours (Solheim et al., manuscript 
submitted for publication) and others (8) implicating V38 
TCR in syngeneic CTL responses  to L  d plus peptide,  we 
sought to define the role of V~8 + CTL in aUogeneic re- 
sponses. Primary CTL specific for L  a were generated using 
splenic  lymphocytes  from  the  Ld-loss  mutant  din2  as 
responders and irradiated wild-type BALB/c splenocytes  as 
stimulators.  To  determine whether V/38  +  CTL were in- 
volved in this response to L a, the anti-V/J8 mAb F23.1 was 
added to the 4-h SlCr-release assay to block target cell rec- 
ognition. In the experiment shown in Fig.  1 a, the mAb 
F23.1 was found to block CTL recognition of L  d by •80%o. 
Furthermore, this blocking was specific since the din2 re- 
sponse to Kb/D  b molecules was not blocked by F23.1  (Fig. 
1 b). Even though specific blocking of L d by F23.1 was ob- 
served in three of four experiments, the level of blocking was 
variable (range 30, 60, and 80%). It is noteworthy, however, 
that better blocking was observed if F23.1 mAb was added 
to both the sensitization and assay cultures (data not shown). 
This blocking suggests that a signifcant component of the 
primary response to L  d involves V38 + T cells. The basis for 
the variable blocking by F23.1 could reflect either variability 
in TCR usage among Ld-reactive allo-CTL, or that F23.1 
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Figure 1.  Inhibition of target cell recognition by in vitro primary 
a]lo-L  d CTL by antibody  to VBS. (a) Primary  Ld-specific  CTL were as- 
sayed against RI.IL  a in the presence ((>) or absence (O) of mAb F23.1. 
Controls included  unstiraulated  din2 effector  cells tested on RI.1L  a (A) 
and La-specitic effector  cells tested on R1.1 (I-1). (b) Primary Kb/D  b- 
specific CTL were analyzed  against EL-4 in the presence (O) and ab- 
sence (O) of  mAb F23.1. Controls  consisted  of  unstimulated  din2  effector 
cells analyzed  against EL-4 (A) and Kb/Db-specific effector  cells tested 
against R1.1 (FI). 
37  Goss et al. does not block ef~ciently. For these studies we utilized the 
Ld-transfected thymoma target ILl.1 which is FctL negative, 
thus ruling out the possibility of FcR-mediated redirected 
lysis. Therefore, poor blocking could be attributed to either 
F23.1 having a lower affinity for V138 than V~8 has for L  d, 
or that the F23.1 site on V~8 is sterically distinct from that 
involved in L a recognition.  To resolve this issue we used 
F23.1  in vivo depletion of V138 ceils (21) to determine the 
extent of the contribution of V/38 + T  ceils to the genera- 
tion of a primary response to L a. 
Effect of In  Vivo Administration  of the mAb f:23.1.  To in 
vivo  deplete  the  V/38  +  T  lymphocytes, din2  mice were 
given three 500-#g i.p.  injections of affinity-purified 1:23.1 
mAb on days 0, 2, and 4. Approximately 72 h after the third 
injection, the spleen cells were harvested, pooled, and ana- 
lyzed for the expression of the V/38 TCK and CDS. Whereas 
in control din2 mice, 5-7% of the peripheral spleen cells were 
found  to  be  V/38 +  CD8 +,  the  F23.1-treated  dm2  mice 
showed virtually complete depletion of all CD8 + V/$8 + T 
lymphocytes (Fig. 2). Similar results were seen in five inde- 
pendent cytometry experiments run as controls for subse- 
quent CTL and aUograft studies. It should be noted that after 
F23.1  treatment,  staining with the secondary fluorescein- 
conjugated  goat  anti-mouse  IgG  alone  was  negative on 
V/38 § T ceils. This result indicates that the failure to detect 
V/38 + T  ceils was not due to to antibody blocking by the 
F23.1 mAb as a result of the in vivo treatment. At present, 
it appears  that the loss of V/38 + T  ceils was a result of T 
cell depletion and not TCR modulation. FACS  ~ profiles gener- 
ated after the in vivo administration of F23.1  did not dem- 
onstrate downregulation of either the TCR alone or the TCR 
in combination with CD8 (Fig.  2), in apparent contrast to 
recent studies by Teh et al. (22) or l%cha and yon Boehmer 
(23).  The VB8 § T  lymphocytes did not begin to reappear 
in the spleen and axillary lymph nodes until "6 wk after 
F23.1 administration, which was the longest interval evalu- 
ated(data not shown). 
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Figure 2.  Depletion ofV~8 + T cells by in vivo treatment with F23.1. 
Two-color flow cytometry analysis of V/~S TCK and CD8 expression was 
performed on spleen cells from (a) control din2 mice and (b) dm2 mice 
treated intraperitoneally with 1,5 mg 1=2.3.1 mAb. Cells were incubated 
with mAb 1=23.1 and developed with HTC-conjugated goat anti-mouse 
IgG, This was followed by incubation with biotinyhted antibody to CD8, 
and developed with streptavidin PE. 
Primary Anti.H.2L a Response  To define the effect of in vivo 
V/38 + T  lymphocyte depletion on the in vitro anti-H-2L  a 
and anti-H-2  b allogeneic immune responses, pooled spleen 
cells from F23.1-treated or control saline-treated din2 mice 
were  stimulated  in  vitro  for  5  d  with  the  Ld-disparate 
BALB/c or fully MHC-disparate C57BL/6 spleen cells. At 
the completion of this culture period, the CTL were ana- 
lyzed for specific cytolytic activity. As shown in Fig. 3 a, 
depletion of the F23.1 + lymphocytes resulted in a marked 
decrease in the anti-H-2L  a cytolytic response in comparison 
with the control din2 CTL, which demonstrated strong cyto- 
lytic activity against the Ld-disparate  targets.  In contrast, 
depletion of the V/38 + T lymphocytes did not alter the anti- 
H-2  b response (Fig.  3  b). These data demonstrate that the 
ailogeneic din2 anti-L  a primary response preferentially uses 
the Vfl8 gene family and that the in vivo depletion of these 
T  cells abrogates this primary response. Additionally, this 
effect is L a specific since the depletion of Vfl8 T  ceils did 
not affect the response to Kb/D  b antigens (Fig.  3  b). 
Effect of In Vivo Depletion of Vr  + T Lymphocytes on L d- 
disparate Stdn AllografiSurvival.  Because of these dramatic 
in vitro results, we wanted to determine the role of Vfl8 + 
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Figure 3.  In vivo depletion of V/S8  § T ceils specifically abhtes the pri- 
mary dm2 anti-H-2L  a response. (a) Primary La-specitic CTL were assayed 
against P815 after in vivo treatment with saline (O) or 1.5 mg F23.1 i.p. 
([~). Controls consisted of saline-treated  (<)) and P23.1-treated  (A) L  d- 
specific CTL tested against the third party EL4 target. (b) Primary K~/D  b- 
specific CTL were tested against EL-4 after in vivo treatment with saline 
(O) or F23.1 (l-q). Controls include cytolytic activity against the third 
party target P815 by saline (O) and F23.1-treated  (A) effector cells. 
38  Anti-V/~8 Prolongs Ld-disparate Allografr Survival Table  1.  Mouse Strains and Tumor Target Cell Lines  Used 
Class I  and II 
Mouse strain  Haplotype  molecule expressed 
BALB/c  H-2  d  KaAdEaDaLa 
BALB/c-H-2am2  H-2  din2  KaAaEaD a- 
BALB.K  H-2  ~  KkAkEkD k 
C57BL/6  H-2  b  KSAbD  b 
B10.HTT  H-2  ~  K'A'EakD%  a 
B10.AKM  H-2  m  KkAkEkDqL  q 
Cell Lines 
P815  H-2  a  KODaL  a 
EL  -4  H -2  b  KbD  b 
ILl.1  H-2  k  K~Dkt 
R1.1L  d  H-2  ~  KkDkL  d** 
* Ld-transfected R1.1 target  cell line. 
t FcR-negative  target  cell line. 
T  lymphocytes  in La-disparate, haplotype-mismatched and 
single Dk-locus-disparate skin graft rejection. Female control 
untreated din2 mice and din2 mice treated with 500/~g F23.1 
(days -2, 0, and + 3) received two skin grafts (Table 1). The 
right dorsal thorax was engrafted with a full thickness BALB/c 
(H-2  a) abdominal skin graft,  and the left dorsal thorax was 
engrafted with a C57BL/6  (H-2  b) abdominal skin graft. 
Whereas F23.1-treated female din2 mice rejected the H-2  b 
skin grafts in a time similar to control animals, the H-2  d 
skin graft survival was significantly prolonged by about 10 d 
in comparison  with controls ~  <0.01) (Fig. 4, A  and B). 
To properly control for nonspecific effects of the antibody 
treatment, din2 female mice were treated with the isotype- 
matched mAb KJ23 that is specific for V/317. As shown in 
Fig. 4 C, mice treated with purified KJ23 antibody rejected 
La-disparate grafts in a fashion comparable with untreated 
control recipient  mice. Thus,  the above La-disparate graft 
prolongation observed with F23.1 was specific  and attributable 
to the depletion of V~/8  + T lymphocytes.  To further char- 
acterize the aUoantigenic specificity of this graft  prolonga- 
tion, transplants across other MHC disparities were also tested. 
To determine whether grafts differing by L  d in addition to 
other class I and II alloantigens were affected  by F23.1, treated, 
din2 mice were grafted with B10.HTT (K', A ', E  '/k, D a, 
L d)  skin.  These skin grafts were rejected by control dm2 
mice in 11.2 _+ 0.9 d, whereas the F23.1-treated din2 mice 
rejected these BI0.HTT skin grafts in 11.3 +  0.8 d, which 
is not significantly different than controls (Fig. 5 A). Since 
there was no prolongation in skin aLlograft survival in this 
complete MHC-disparate combination, we next analyzed skin 
graft survival with F23.1 treatment in a strain combination 
that differed only at the MHC class I locus D k. To confer 
specificity for only D k alloantigens, we bred Ft hybrids be- 
tween dm2 and B10.AKM (Kk,Ak,EI~,Dq,Lq).  These Ft mice 
A 
100( 
"~  eot 
,o[- 
;r  2o i- 
Oi  I  I  I 
240 
din2 a BALBIc 
F23.1 
i"i.  ' 
, n-13 i 
8  10  12 
Days 
q  q 
,  ,~,  n-13 
J  a  J  i  I  I 
14 16 18 20 22 24 26 28 30 
of Survival 
B  dm2 ~ C57BLI6 
F23.1  loo[  I 
eol-  --!1 
(~  40~"  il 
n-l, 
0  /  t  i  i  1  t  :1  J  ,  I  I  I  I  I  !  I 
2  4  6  8  10 12 "14 16 18 20 22 24 26 28 30 
Days of Survival 
C  dm2 a BALB/o 
KJ23 
m~  '  '  "1  I  i.,  r  40 
2o  n  n-8 
0  t  t  t  ~  i  I  I  i  i  , 
2  4  6  8  10  12  13  14  16  18 20 22 24 26 28 
Days of Survival 
Figure 4.  In vivo depletion of V/~8  + CTL specifically prolongs L  d- 
disparate skin allograft survival. (A) Control din2 mice (- - -) rejected 
BALB/c skin allografts in 10.3 •  1.1 d. BALB/c skin allograft survival 
was significantly (p < 0.01 vs. control) prolonged on din2 mice treated 
with the mAb F23.1 (  ) (MST 22.1  +  2.1 d) (/3). The in vivo ad- 
ministration of F23.1 to dm2 recipients does not prolong C57BL/6 skin 
allograft survival. Control din2 (- - -) rejected C57BL/6 skin grafts in 
9.7 •  0.9 d, whereas F23.1-treated din2 (  ) rejected C57BL/6  skin 
grafts in 11.8 +  1.9 d. ((7) In vivo treatment of the din2 recipient with 
the isotype-matched mAb KJ23 does not prolong BALB/c skin allograft 
survival. Control din2 (- - -) and KJ23-treated (~)  dm2 mice rejected 
BALB/c skin allografts in 11.1  •  1.7 and 11.9 •  1.5 d,  respectively. 
were grafted with skin from BALB.K (H-2k). Thus the only 
genetic disparity between the FI recipients and the BALRK 
donor is the D k locus, because they are genetically matched 
at other class I, class II, and non-MHC loci. All BALRK 
skin  grafts  were  rejected  by  control  and  F23.1-treated 
(B10.AKM  x  drn2)Ft  mice in  similar  fashions,  (control 
mice rejected the BALB.K skin grafts in/1.8 +  1.0 d, whereas 
F23.1-treated mice rejected these grafts in 12.1 +  1.2 d) (Fig. 
5 B). These skin graft results indicate that the depletion of 
V/~8 + T lymphocytes does not affect allogeneic responses to 
all MHC antigens.  Thus V/~8  + T lymphocytes play a cen- 
tral and spedfic role in the primary response to L d aUoan- 
tigens. 
To assess the possibility  that the VB8 + T  lymphocytes 
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Figure 5.  The in vivo depletion ofVB8 + T lymphocytes does not pro- 
long fully MHC-disparate B10.HTT skin aUografr survival. (,4) Control 
dm2 (- - -) mice rejected B10.HTT skin allografrs in 11.2  _+ 0.9 d. The 
survival time of these skin aUografts is not prolonged by the in vivo ad- 
ministration of F23.1 to the din2 recipient (  ) (MST 11.3 _+ 0,8 d). 
(/3) In vivo F23.1 administration does not prolong the MHC class I-disparate 
rejection of BALB.K skin allografts by (B10.AKM  x  dm2)F1 mice, The 
control (B10.AKM  x  dm2)Fl (- - -) mice rejected BALB.K skin in 11.8 
+  1.0 d. F23.1 treated (B10,AKM  x  dm2)Fl (  ) rejected BALB.K 
skin allografts in a similar fashion  (MST 12.1  +  1.2 d). 
had repopulated the peripheral lymphoid circulation and medi- 
ated the anti-H-2L  d skin allograft  rejection response in the 
VB8-depleted recipients, flow cytometry evaluation of the pe- 
ripheral lymphoid system was performed. At the completion 
of rejection of both the H-2  b and H-2  d skin grafts,  spleen 
cells and draining axillary lymph node lymphocytes  were har- 
vested and evaluated for the presence of VB8 + T  lympho- 
cytes by flow cytometry. The control din2 spleen cells con- 
tained  5-8%  CD8 +  VB8 +  T  cells  (Fig.  6  a)  whereas 
F23.1-treated dm2 mice, despite rejecting an H-2  d skin graft, 
did not possess CD8 + V38 + T  cells (Fig.  6 c).  Identical 
results were obtained with axillary lymph node lymphocytes 
indicating that the V~8 + T cells were not concentrating in 
the region of the graft. These results demonstrate that the 
V~8 + T  cell population plays a dominant role in the pri- 
mary response to L  a and that, in the absence of a V38 T 
cell response, a secondary T lymphocyte population develops 
after  a delay  and effects rejection of the La-disparate skin 
graft. 
Effect of In Vivo Depletion of V,88 + T  Lymphocytes on the 
Secondary  Anti-H-2L ~ Allogeneic  Response.  Since  V~8- 
depleted dm2 mice did ultimately reject their L~-disparate 
grafts,  it was interesting to characterize  the nature of this 
response. After the complete rejection of BALB/c skin grafts 
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Figure 6.  Secondary anti-L  a response generated by a VB8- population. 
Two-color flow cytometry analysis of VB8 TCR and CD8 expression was 
performed at the completion of skin graft rejection on spleen cells from 
(a) control din2 mice and (c) din2 mice treated with F23.1. Cells were 
incubated with mAb F23.1  and developed with FITC-conjugated goat 
anti-mouse. This was followed by incubation with biotinylated antibody 
to CDg, developed with Streptavidin PE. Secondary Ld-specific  CTL from 
(b) saline-treated control din2 and (d) FZ3.1-treated din2 mice (Fdm  2) were 
assayed against RI,ILd and R1.1 at an effector/target ratio of 100:1 at the 
completion of skin graft rejection. 
by untreated control and F23.1-treated dm2 mice, pooled spleen 
cells were stimulated with BALB/c irradiated spleen cells for 
5 d. Secondary CTL were evaluated for anti-L  a cytolytic ac- 
tivity utilizing the Ld-transfected target cell line P,1.1 and 
the nontransfected R1.1 cell line. Control and F23.1-treated 
secondary CTL demonstrated cytolytic activity against  the 
Ld-transfected R1.1 cell line, but not the R1.1 cell line,  as 
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Figure 7.  Ld-disparate cardiac allograft survival is prolonged by the in 
vivo depletion of VB8 + T lymphocytes. Control saline-treated din2 mice 
(O) rejected BALB/c cardiac aUografts with a MST of 8.6  +_ 0.5 d. In 
contrast, BALB/c allograft survival was significantly prolonged (MST > 
100 d, p < 0.01) when VB8 + T lymphocytes were depleted in din2 re- 
cipient mice using F23.1  (A). 
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totoxicity in the V~8 + T  lymphocyte-depleted host con- 
firm that the anti-L  a allogeneic response can occur after a 
prolonged exposure to antigen in the absence of V~/8 + T 
lymphocytes and suggest that lymphocytes expressing other 
T cell receptors not affected by the F23.1 mAb are playing 
a role. In support of this contention, anti-L  a CTL lines from 
F23.1-treated mice were propagated in vitro for an additional 
4 wk and shown to lack the V~8 TCR by flow cytometric 
analysis (data not shown). It is noteworthy that the targets 
used in Fig. 6 are MHC class II-negative, thus the cytotox- 
icity observed was presumably CD8 + CTL recognizing in- 
tact L  d and not CD4 + CTL recognizing processed  L  d. 
Effect of In Vivo Depletion of V~8 + T Lymphocytes on La- 
disparate Cardiac Allografi Survival.  Because the in vivo deple- 
tion  of VB8 +  T  lymphocytes resulted in  prolonged L a- 
disparate  skin graft survival,  we next attempted to extend 
this observation to the less immunogenic  vascularized cardiac 
allograft by utilizing a heterotopic cardiac transplantation 
model. Control untreated din2 mice rejected  Ld-disparate 
BALB/c cardiac allografts in 8.6 + 0.5 d (Fig. 7). Histologic 
evaluation of BALB/c cardiac allografts removed at the com- 
plete cessation of ventricular contraction demonstrated a typical 
dense mononudear cell infiltration and associated myofibril 
necrosis consistent with allograft rejection. In contrast, the 
mean survival time of BALB/c cardiac allografts in din2 mice 
that were treated with 500 #g F23.1 on days -2,  -1,  +3, 
+25,  +50,  and  +75 was prolonged to >100 d (p <  0.01 
vs. control). Additional antibody was given to these animals 
on days 25, 50, and 75 to ensure that the V~8 + T cells did 
not repopulate the circulation. Histologic evaluation of these 
BALB/c hearts removed 100 d after heterotopic transplanta- 
tion demonstrated healthy cardiac myocytes without mononu- 
clear cell infiltration or evidence of tissue damage. Therefore, 
in the less immunogenic  vascularized cardiac allograft, removal 
of the VB8 § T  lymphocyte population eliminates the pri- 
mary response and thereby allows dramatically prolonged sur- 
vival of the allograft.  The prolongation of BALB/c cardiac 
allograft survival by the depletion of VB8 § T lymphocytes 
in the dm2 recipient thus extends the observation to a second 
organ and confirms that the V~8 TCR gene family plays a 
pivotal role in the primary immune response to H-2L  a al- 
loantigen. 
Discussion 
As a model system to study the TCR gene usage of a defined 
aUoantigen,  we have studied allorecognition of the murine 
L  a molecule. We report here that in vivo treatment with the 
VBS-spedfic mAb F23.1 diminates all detectable peripheral 
VB8 + T lymphocytes. This in vivo depletion was found to 
abrogate a subsequent primary in vitro response of din2 cells 
to L  d. Additionally, the depletion of V/~8 + T lymphocytes 
significantly prolonged survival of Ld-disparate skin and even 
more dramatically prolonged vascularized heart aliografts. This 
abrogation of the dm2 anti-L  d response was MHC specific 
in that in vivo depletion of VB8 + CTL had no effect on the 
in vivo or in vitro response of din2 homozygous or hetero- 
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zygous mice to other class I alloantigens.  Thus, the in vivo 
administration of the mAb F23.1  results in a  substantial 
MHC-specific abrogation of the primary din2 response to 
L d alloantigens.  These findings demonstrate that TCR with 
VB8 segments predominate in the in vivo and in vitro pri- 
mary responses to the L a alloantigen. This finding of a pre- 
dominant TCR usage in allogeneic responses to MHC mol- 
ecules is in agreement with certain studies (e.g.,  11,  12), 
whereas others have reported finding high levels of TCR diver- 
sity (13-15). The reported diversity of allorespousiveness  could 
be explained by either structural differences among class I 
alloantigens (24) or their respective ligands (25). For example, 
the high level ofpolymorphism  among class I molecules results 
in  '~20%  differences between the amino acid residues  of 
different K, D, or L molecules (26). Furthermore, most of 
these differences are located in the otl/ot2 domains at posi- 
tions where they could affect TCR recognition of class I ei- 
ther directly or indirectly via ligand binding (27). Given that 
the L  d molecule is as different from D d and K d molecules as 
they are from each other (26),  the lack of diversity in the 
TCR response to L  a alloantigens is probably not due to 
insufficient polymorphism. Another contributing factor in 
the complexity of the alloresponse to class I could be the role 
of the bound peptide ligand. Although still somewhat con- 
troversial, several studies indicate that certain aUoreactive (28) 
and xenoreactive (29) TCR to class I can discriminate self- 
peptide llgands. Furthermore, a given class I molecule  is dearly 
capable of binding numerous sdf-peptide ligands (30). There- 
fore, if the bound peptide ligand plays a role in allorecogni- 
tion,  diversity in  the TCR gene family usage would be 
anticipated. Given that L  a molecules, like K and D  alloan- 
tigens, have been shown to bind several different immuno- 
genic or sdf-peptides (31-33),  the lack of TCR diversity of 
L a alloantigens is presumably not due to its inability to bind 
a variety of ligands.  Thus, there are no obvious structural 
differences between L  a and other dass I molecules and their 
respective ligands that might explain why the alloresponse 
of din2 mice to L d should show such a limited V~8 usage. 
However, based on the recent modal of Davis and Bjorkman 
(7),  speculations can be made that might explain  the pre- 
dominance of V~88 in TCR recognition of L  d. 
Although the precise manner by which TCR and class 
I-peptide interact is unclear, a very intriguing model has been 
recently proposed. Even though TCR molecules have not 
yet been crystallized, based on structural similarities with Ig, 
their respective V domains are likely to display comparable 
folding. Furthermore, the three hypervariable regions of Ig 
(CDR1-3), known to form the principal contact points of 
Ig with antigen, are located at equivalent locations in TCR 
gene products. Given these similarities  between TCR and 
Ig, Davis and Bjorkman (7) proposed a modal of how MHC 
molecules and TCR might interact. In this model, the CDR1 
and CDR2 regions of Vc~ and V~/of the TCR would in- 
teract with the ot hdical portions of the r  dass I mole- 
cule. Furthermore, the CDR3 region located in the V(D)J 
junction would interact with bound peptide (34).  Indeed, 
there are several findings consistent with this modal (cf 11, 
12). In the context of this model, speculations can be made as to why the L  a alloresponse  might show a predominant 
V~8 usage.  Perhaps the predominance of VB8 recognition 
of L  a is determined by the structure of its c~ helical regions 
independent of the bound peptide ligand. Fortuitously, the 
CDK1 and CDR2 regions of V158 could have an at~nity for 
surface residues in the o~ helical regions of L d. This expla- 
nation is supported by the observations that V~8 predominates 
in both alloreactive (data presented here) and syngeneic peptide- 
specific responses restricted to L  a in BALB/c mice. In these 
studies of La-restricted syngeneic responses, Kodewald et al. 
(8)  demonstrated  a  3-5-fold  higher  L  a-  restricted  CTL 
precursor frequency in V/58 + T lymphocytes compared with 
V158- T  lymphocytes after infection with CMV; and Sol- 
heim et al. (manuscript submitted for publication) found a 
dominant usage of VB8 by La-restricted CTL clones specific 
for the tuna-  peptide. Thus V138 predominates in both al- 
logeneic and at least certain peptide-specific  responses restricted 
by L  a in mice of the BALB/c genetic background. It will 
be very interesting to determine whether this extends to mouse 
strains of other genetic backgrounds. 
An alternative explanation for the predominance of V138 
usage is that it is determined by the peptide ligands bound 
to L  a. Although L d presents many different peptides, per- 
haps a high proportion of alloreactive CTL to L  a recognize 
the same dominant sdf-peptide or peptides of a common struc- 
tural motif. However, predominant V138 usage has also been 
observed in syngeneic peptide-specific responses to L d, and 
these latter CTL display exquisite peptide specificity. Fur- 
thermore, the primary region of the TCR thought to in- 
teract with the bound peptide is CDK3 which is located in 
the junctional region, not the V segment alone (34). Thus, 
it appears more likely that the predominant usage of VB8 
found in responses  restricted by L  a is independent of the 
bound peptide. Regardless  of which of the above explana- 
tions is correct, the predominance of V~8 usage reported here 
provides an important insight into TCK recognition of an 
allogeneic dass  I  molecule.  It  was  noted by  Davis  and 
Bjorkman (7) that the relative sizes of the interactive surfaces 
of MHC and TCK would allow binding in different registers 
along the MHC ol helices. Thus the V genes employed by 
different T cells restricted to the same MHC molecule would 
not be expected to be identical. By contrast, our data would 
suggest that at least V138 and L a interact primarily along a 
single register as defined by the predominance of VB8 in al- 
logeneic and MHC-restricted responses. 
In conclusion, the findings here may have clinical relevance 
for the design of transplantation immunotherapies. Previous 
studies of end stage  rejection of transplanted tissues have 
demonstrated heterogeneous TCR usages. This heterogeneous 
response is predictable however, based on the fact that at end 
stage rejection there would be recruitment of large numbers 
of T lymphocyte specificities due to both nonspecific factors 
produced as a result of inflammatory processes and specific 
recruitment ofT lymphocytes  reactive with potentially tissue- 
specific cryptic epitopes exposed as a result of tissue destruc- 
tion. Recent reports in the human have indicated that, similar 
to the data presented here, initial rejection episodes demon- 
strate a preferential TCK usage for the bulk of the response 
(12). Therefore, if specific TCK therapies could be designed 
to block the initial predominant rejection response, perhaps 
the second line of recruitment and rejection may be more 
easily managed with lower doses of conventional immunother- 
apies and thereby decrease host susceptibility to opportunistic 
infections and malignancies. In addition, EAE has been treated 
with TCR peptides derived from the predominantly selected 
variable regions (35, 36). Recent data reported by Lehmann 
et al. (37) supports our hypothesis that if the first line im- 
mune response is abrogated early, the secondary response may 
also be downregulated. Lehmann et al.  (37) demonstrated 
in the experimental allergic encephalitis model specific pep- 
tide therapy during primary disease induction processes in- 
activates the primary TCK donally restricted effector cells, 
abrogating the inflammatory reaction in the central nervous 
system, a prerequisite for second wave priming. However, 
after determinant spreading has occurred, as a result of cen- 
tral nervous system inflammatory processes, anticlonotypic 
therapy may no longer be effective  in therapeutically managing 
the diversified autoreactive T cell pool in more advanced dis- 
ease. Indeed, our preliminary studies indicate that a peptide 
derived from  the  CDR2  region  of V138.2 can  prolong 
Ld-disparate allografts.  Thus peptide therapy may also be 
effective for the prevention and treatment of allograft rejec- 
tion when a predominant TCK gene family usage can be 
identified. 
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